Mark J. Ratain, MD, is an expert in the use of investigational agents to treat advanced solid tumors in addition to his specialty in the clinical pharmacology of marketed drugs. Dr. Ratain has an interest in the clinical development of new oncology drugs, and more recently, his research focused on the use of pharmacogenomics to guide personalized prescribing and interventional pharmacoeconomics. Through this research, he is aiming to decrease prescribing costs through the use of lower dosages, less frequent dosing, shorter duration of treatment, and/or therapeutic substitution.
Dr. Ratain is an international leader in phase I clinical trials, pharmacogenetics and clinical trial methodology, and he created the new discipline of interventional pharmacoeconomics. His work can be found in more than 500 published articles and book chapters.
He has also received several awards/recognitions for his dedication to improving medicine. In 2015, Dr. Ratain received the Award in Excellence in Clinical Pharmacology from the Pharmaceutical Research and Manufacturers of America Foundation. In 2016 he was the nominee (Scientific Advances), from the Giants of Cancer, OncLive and in 2019 Dr. Ratain presented the Gruber Lectureship at Thomas Jefferson University.
Specialties
Areas of Expertise
- Solid Tumors
Board Certifications
- Internal Medicine
- Hematology
- Medical Oncology
Memberships & Medical Societies
- American College of Physicians
- American Association for Cancer Research
- Central Society for Clinical and Translational Research
- American Association for the Advancement of Science
- American Society of Hematology
- Association of American Physicians
- European Society for Medical Oncology
- American Federation for Clinical Research
- American Society for Clinical Pharmacology and Therapeutics
- American Society of Clinical Oncology
Practicing Since
- 1986
Languages Spoken
- English
Medical Education
- Yale University
Internship
- The Johns Hopkins Hospital
Residency
- Johns Hopkins Hospital
Fellowship
- University of Chicago Medicine
News & Research
View Published Papers- Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
- An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread
- A Study of XmAb®18087 in Subjects With NET and GIST
- A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
- A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies
- Aetna HMO (specialists only)
- Aetna POS
- Aetna PPO
- BCBS Blue Precision HMO (specialists only)
- BCBS HMO (HMOI) (specialists only)
- BCBS PPO
- Cigna HMO
- Cigna POS
- Cigna PPO
- CountyCare *see insurance page
- Aetna Better Health *see insurance page
- Medicare
- Multiplan PPO
- PHCS PPO
- United Choice Plus POS/PPO
- United Options (PPO)
- United Select (HMO & EPO) (specialists only)
- United W500 Emergent Wrap
- Aetna Medicare Advantage HMO & PPO
- BCBS Medicare Advantage HMO & PPO
- Humana Medicare Advantage Choice PPO
- Humana Medicare Advantage Gold Choice PFFS
- Humana Medicare Advantage Gold Plus HMO
- United Choice HMO (specialists only)
- University of Chicago Health Plan (UCHP)
Our list of accepted insurance providers is subject to change at any time. You should contact your insurance company to confirm UChicago Medicine participates in their network before scheduling your appointment. If your insurance company is not listed here, or if you have any other questions, please contact Managed.Care@uchospitals.edu.
Duchossois Center for Advanced Medicine (DCAM) - Hyde Park
Request an Appointment at Duchossois Center for Advanced Medicine (DCAM) - Hyde Park
To Refer a Patient
Refer a Patient